Standard BioTools reports Q2 2026 results, says Treeline merger on track to close by year-end

Standard BioTools Inc. said its merger with Treeline Biosciences is progressing toward stockholder vote and anticipated to close before year-end 2026.¹ CEO Michael Egholm said the company remains on track to close the merger with Treeline Biosciences in 2026, with its previously filed registration statement on Form S-4, its agreement to divest its Mass Cytometry business, and Illumina's early buyout of contingent payments for $30 million from its acquisition of SomaLogic.¹ He added the company continues to believe this merger is the best path forward to maximize shareholder value, providing exposure to a catalyst-rich, well-capitalized pipeline of potential new therapeutics, and looks forward to updating stockholders as it progresses toward the vote and closing.¹

Because of the pending deal, Standard BioTools is withdrawing its full year 2026 revenue outlook given the pending merger with Treeline Biosciences.¹

On financial standing, the company reported cash, cash equivalents, restricted cash, short-term and long-term investments of $541.1 million as of June 30, 2026, versus $227.9 million a year earlier.¹

For the quarter, revenue was $20.1 million, down from $21.8 million in the prior-year quarter, while adjusted EBITDA improved to a loss of $2.5 million from a loss of $16.1 million.¹ Operating expenses included $14.7 million in transaction costs and $2.8 million in restructuring and related charges.¹

The company noted risks tied to the transaction, stating that the merger may not be completed on the anticipated timeline or at all, including risks related to obtaining stockholder approval and satisfying other closing conditions,¹ and that the Mass Cytometry sale similarly may not close on the anticipated timeline or at all.¹